Cardiovascular Dysfunction in Post-COVID ME/CFS
The COVID-19 pandemic has provided an unfortunate natural experiment in post-infectious illness, with Long COVID (post-acute sequelae of SARS-CoV-2, PASC) showing remarkable overlap with ME/CFS cardiovascular manifestations. This convergence strengthens the evidence for shared pathophysiological mechanisms and may accelerate therapeutic development.
1 Parallel Cardiovascular Findings
Long COVID patients demonstrate cardiovascular abnormalities closely mirroring those documented in ME/CFS, including POTS (affecting 30–50% of Long COVID patients with persistent symptoms), reduced exercise capacity on CPET with similar patterns of reduced VO2peak and early anaerobic threshold, autonomic dysfunction with altered HRV and baroreflex sensitivity, and endothelial dysfunction with impaired flow-mediated dilation (Devigili et al. 2023).
Small fiber neuropathy has been documented in both conditions using identical methodologies. Azcue et al. found that ME/CFS and post-COVID patients showed comparable patterns of heat response latencies indicating C-fiber denervation (Azcue et al. 2023). The non-length-dependent pattern observed in both conditions suggests autoimmune or inflammatory etiology rather than metabolic neuropathy.
A 2026 study extended these findings from somatic to visceral autonomic fibers. Acanfora et al. performed gastric mucosal biopsies (fundus and antrum) in 12 Long COVID patients and 8 dyspeptic controls, quantifying nerve fiber density by 3D reconstruction of PGP 9.5 (pan-neuronal) and vasoactive intestinal peptide (VIP, a cholinergic marker) immunostaining (Acanfora et al. 2026). Long COVID patients showed significantly reduced mucosal innervation (fundus PGP 2.1 vs 3.9 nm/µm3, \(p<0.01\); antrum 1.9 vs 3.9, \(p<0.05\)), with a disproportionate loss of VIP-positive cholinergic fibers, most marked in the fundus. Crucially, intraepidermal nerve fiber density (skin) did not differ between groups, indicating that the denervation was selectively visceral rather than a generalized small fiber neuropathy. Gastric nerve density correlated with autonomic function (HRV LF/HF ratio \(R=0.50\), \(p<0.05\)) and with cardiovascular-stress biomarkers (NT-proBNP \(R=0.52\); D-dimer \(R=0.61\)); these are modest correlations on \(n=12\) (\(r^2 \approx 0.25\)–$ 0.37$, leaving most of the variance unexplained and consistent with many drivers of HRV and coagulation beyond nerve density), so they are best read as hypothesis-generating rather than as evidence of a tight mechanistic link. Two confounds further limit interpretation: the finding cannot distinguish vagal from enteric fibers, and deconditioning — near-universal in Long COVID — can itself reduce both HRV and, plausibly, mucosal innervation, so the denervation could be a consequence rather than a cause of the illness state. The dyspeptic control group is also a limitation: functional-dyspepsia patients may have altered baseline gastric innervation, leaving the direction of any comparison bias unknown. Whether any of this holds in ME/CFS has not been tested.
Certainty: 0.45. Evidence type: single observational case–control study (\(n=12\) vs $ 8\(), not replicated.* Acanfora et al.\ [@acanfora2026vagaldenervation] report the first in vivo morphological observation that autonomic dysfunction in Long COVID may reflect an underlying structural lesion — selective loss of cholinergic (VIP+) nerve fibers in the gastric mucosa, sparing somatic skin fibers — with nerve density correlating with HRV vagal indices (\)R=0.50$). This is a preliminary finding, not a settled result: certainty is held at 0.45 by the small single-center sample, dyspeptic (not healthy) controls, no recovered-asymptomatic COVID group, the inability to distinguish extrinsic vagal from intrinsic enteric fibers, the deconditioning confound, and the absence of independent replication. It has never been demonstrated in ME/CFS. It could be complementary to — or, alternatively, made redundant by — the functional* CAP-blockade model proposed for GPCR autoantibodies (Chapter Integrative Models and Multi-System Pathophysiology, Speculation Cholinergic Anti-Inflammatory Pathway Blockade by GPCR Autoantibodies — Potential Mechanism for Vagal Treatment Stratification): one describes structural fiber loss, the other antibody-mediated signaling interference, and current evidence cannot establish that both (or either) operate in ME/CFS.
Consequence: If post-viral illness can physically destroy vagal nerve fibers (not just impair their signaling), this points toward a potentially harder-to-reverse form of autonomic damage; the distinction between structural fiber loss and reversible functional impairment is worth testing directly rather than assuming, because it bears on whether autonomic dysfunction should be treated early — but this is a Long COVID finding from one small unreplicated study, and whether the same structural loss occurs in ME/CFS remains an open and testable question.
2 GPCR Autoantibodies in Post-COVID
The GPCR autoantibody hypothesis has received substantial support from post-COVID research. Elevated beta-adrenergic and muscarinic receptor autoantibodies have been documented in Long COVID patients with cardiovascular symptoms, and immunoadsorption targeting these autoantibodies has shown efficacy in post-COVID ME/CFS (Stein et al. 2025). The Scheibenbogen group demonstrated that repeated immunoadsorption in patients with post-COVID ME/CFS and elevated beta-2 adrenergic receptor autoantibodies produced significant improvements in fatigue and autonomic symptoms.
Hackel et al. demonstrated that GPCR autoantibodies reprogram monocyte function in post-COVID ME/CFS, altering cytokine production patterns and potentially explaining systemic inflammatory features (Hackel et al. 2025). This finding links autoantibodies to immune dysfunction beyond direct receptor effects, suggesting multiple downstream consequences of the autoimmune process.
3 Implications for Understanding ME/CFS
The convergence of Long COVID and ME/CFS cardiovascular findings supports the hypothesis that both conditions share common post-infectious pathophysiology. The larger Long COVID research effort, driven by the pandemic’s scale, is generating mechanistic insights likely applicable to ME/CFS. Therapeutic interventions developed for Long COVID—including immunoadsorption, GPCR-targeting aptamers, and mast cell stabilizers—may prove equally effective in ME/CFS patients with similar pathophysiology.